Fate Therapeutics, Inc.

As of June 30, 2026, Fate Therapeutics, Inc. carries a market capitalization of 275.63M, placing it among publicly traded companies globally. Its enterprise value stands at 207.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fate Therapeutics, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Fate Therapeutics, Inc. has 116.69M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 49.75, and the price-to-book ratio stands at 2.05.

These figures are as of June 30, 2026. The EV/Sales ratio of 36.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 207.28M versus a market cap of 275.63M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Fate Therapeutics, Inc. maintains a current ratio of 4.85, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Fate Therapeutics, Inc. posted a negative return on equity (ROE) of -60.75, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -39.89, reflecting losses generated across the asset base. The company generates approximately 34,226.34 in revenue per employee across its workforce of 166.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Fate Therapeutics, Inc.'s stock has gained approximately 44.97% over the past 52 weeks. The 50-day moving average sits at 2.05, while the 200-day moving average is 1.69.

Over the twelve months ended June 30, 2026, Fate Therapeutics, Inc. generated 5.68M in revenue and converted that into -110.28M in net income, yielding earnings per share of -0.92. EBITDA reached -106.44M, while operating income came in at -116.93M.

As of June 30, 2026, Fate Therapeutics, Inc. holds 134.59M in cash and equivalents against 66.24M in total debt, resulting in a net debt position of -28.39M. Total book value stands at 134.30M, with working capital of 109.73M providing operational flexibility.

Fate Therapeutics, Inc. produced -89.23M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.25M in capital expenditures, free cash flow totaled -92.48M - equivalent to -0.77 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -2,058.08 and net profit margin of -1,941.09 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -32.72: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of June 30, 2026, Fate Therapeutics, Inc. has an Altman Z-Score of -7.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.